Articles By Estel Grace Masangkay

  1. AstraZeneca Bolsters Partnership With U Of Cambridge 10/22/2014

    AstraZeneca and its global biologics R&D arm MedImmune announced four new collaborations with the University of Cambridge, all launched in an attempt to strengthen AZ’s existing partnership with the University as the company sets out to expand its research infrastructure in Cambridge.

  2. Lilly To Streamline Manufacturing Operations In 2015 10/21/2014

    Eli Lilly announced its plans to close one of its three manufacturing plants in Puerto Rico by the end of next year.

  3. Janssen And Aduro Ink New Deal In Lung Cancer Immunotherapy 10/21/2014

    Janssen Biotech and Aduro BioTech announced their second agreement to develop treatments for lung cancer using Aduro’s LADD immunotherapy platform.

  4. ProMetic Seeks Orphan Status For Lead IPF Drug 10/20/2014

    Biopharmaceutical company ProMetic Life Sciences announced its intent to pursue idiopathic pulmonary fibrosis (IPF) as an orphan indication for its lead drug candidate PBI-4050.

  5. Sanofi Ally Shantha Begins Rotavirus Vaccine Phase 3 Trial 10/17/2014

    Sanofi’s vaccine division, Sanofi Pasteur, reported that its affiliate Shantha Biotechnics has initiated the Phase 3 clinical trial in India for its investigational vaccine for rotavirus.

  6. Pfenex, PATH Link Arms For Vaccine Development Model 10/17/2014

    Clinical stage biotech Pfenex announced that it has partnered with international nonprofit organization PATH in a multi-product research initiative to improve vaccine production.

  7. Auspherix, Domainex Join Forces Against Drug-Resistant Infections 10/17/2014

    Early-stage anti-infectives firm Auspherix and U.K.-based drug discovery services firm Domainex announced a new collaboration to develop treatments that will combat antibiotic-resistant bacterial infections.

  8. Nuvilex Files For Orphan Status For Cell-In-A-Box Therapy 10/16/2014

    Clinical stage biotech firm Nuvilex announced that it has submitted an application seeking Orphan Drug Designation for its Cell-in-a-Box treatment for pancreatic cancer.

  9. GAPVAC Vaccine For Glioblastoma Advances To Clinical Trial 10/16/2014

    immatics biotechnologies and its partner BioNTech AG reported that they are advancing the Glioma Actively Personalized VAccine Consortium (GAPVAC) into a Phase 1/2 clinical trial to investigate the concept of fully personalized therapeutic vaccines against cancer.

  10. FDA Accepts Pfizer's NDA For Breast Cancer Drug 10/16/2014

    Pfizer announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for its breast cancer drug palbociclib. The company is seeking approval for palbociclib in combination with letrozole as a first-line treatment for patients with advanced breast cancer.